Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 52-Week High – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price hit a new 52-week high during trading on Friday . The company traded as high as $45.00 and last traded at $45.00, with a volume of 2063 shares traded. The stock had previously closed at $42.45.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 3.24, a current ratio of 1.26 and a quick ratio of 1.26. The stock has a 50 day moving average of $38.50.

Hedge Funds Weigh In On Ascentage Pharma Group International

Large investors have recently bought and sold shares of the stock. Chevy Chase Trust Holdings LLC purchased a new position in Ascentage Pharma Group International in the 2nd quarter worth approximately $227,000. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International in the 2nd quarter worth approximately $391,000. Tema Etfs LLC purchased a new position in Ascentage Pharma Group International in the 2nd quarter worth approximately $610,000. Finally, Monashee Investment Management LLC purchased a new position in Ascentage Pharma Group International in the 1st quarter worth approximately $3,511,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.